Albemarle Corporation $ALB Shares Acquired by CVA Family Office LLC

CVA Family Office LLC boosted its stake in Albemarle Corporation (NYSE:ALBFree Report) by 7,257.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 515 shares of the specialty chemicals company’s stock after purchasing an additional 508 shares during the quarter. CVA Family Office LLC’s holdings in Albemarle were worth $32,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. FengHe Fund Management Pte. Ltd. acquired a new stake in shares of Albemarle during the 2nd quarter worth $32,903,000. PGGM Investments grew its position in Albemarle by 90.4% during the second quarter. PGGM Investments now owns 1,069,924 shares of the specialty chemicals company’s stock valued at $67,052,000 after acquiring an additional 507,975 shares during the period. Nuveen LLC purchased a new stake in Albemarle during the first quarter valued at about $26,836,000. Dimensional Fund Advisors LP increased its stake in Albemarle by 28.7% during the first quarter. Dimensional Fund Advisors LP now owns 1,538,706 shares of the specialty chemicals company’s stock worth $110,814,000 after acquiring an additional 343,210 shares during the last quarter. Finally, Vest Financial LLC raised its holdings in shares of Albemarle by 55.4% in the 2nd quarter. Vest Financial LLC now owns 959,978 shares of the specialty chemicals company’s stock worth $60,162,000 after purchasing an additional 342,321 shares during the period. Hedge funds and other institutional investors own 92.87% of the company’s stock.

Albemarle Price Performance

Shares of ALB stock opened at $105.65 on Monday. The firm has a fifty day simple moving average of $85.52 and a 200-day simple moving average of $71.54. The company has a market capitalization of $12.43 billion, a PE ratio of -11.34 and a beta of 1.65. Albemarle Corporation has a twelve month low of $49.43 and a twelve month high of $113.91. The company has a current ratio of 2.31, a quick ratio of 1.47 and a debt-to-equity ratio of 0.38.

Albemarle (NYSE:ALBGet Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The specialty chemicals company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.94. The firm had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.23 billion. Albemarle had a negative net margin of 18.61% and a negative return on equity of 1.87%. The firm’s revenue was down 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.04 EPS. Albemarle has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Albemarle Corporation will post -0.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ALB. Rothschild & Co Redburn assumed coverage on Albemarle in a report on Friday. They set a “buy” rating and a $135.00 target price for the company. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Albemarle from $74.00 to $95.00 in a research note on Friday, October 17th. Scotiabank raised their target price on shares of Albemarle from $65.00 to $70.00 and gave the company a “sector perform” rating in a research note on Friday, August 1st. JPMorgan Chase & Co. upped their price target on shares of Albemarle from $60.00 to $80.00 and gave the stock a “neutral” rating in a research report on Monday, August 18th. Finally, Cowen reiterated a “hold” rating on shares of Albemarle in a report on Thursday, October 9th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have given a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $95.33.

Get Our Latest Report on ALB

Albemarle Profile

(Free Report)

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.

Recommended Stories

Institutional Ownership by Quarter for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.